Objectives To review the real world evidence in fibromyalgia from last five years identifying
prevalent pharmacological treatment options across US and costs associated for
management of the disease. Methods Embase® and Medline databases were searched
between January 2011 and December 2015. Registries and observational studies in
fibromyalgia population published as full text journal articles in English were included by two
independent reviewers with discrepancies reconciled by a third independent reviewer …

Fibromyalgia (FM) is a chronic disease with a characteristic all over body pain. In 2005, it
was estimated that 2-3% of the American population; 5 million adults were affected by FM.
FM is more prevalent in females (versus males) and between the age group of 60-79 years
(versus younger patients). Currently, there is no cure for FM and various pharmacological
and nonpharmacological treatments are used to manage symptoms of FM. There are three
drugs approved by FDA for use in FM: Pregabalin, Duloxetine, and Milnacipran.